Enovis (NYSE:ENOV) Insider Purchases $23,390.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average price of $23.39 per share, for a total transaction of $23,390.00. Following the completion of the transaction, the insider directly owned 47,640 shares in the company, valued at approximately $1,114,299.60. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Friday, March 6th, Oliver Engert bought 750 shares of Enovis stock. The stock was purchased at an average cost of $24.41 per share, with a total value of $18,307.50.
• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The stock was acquired at an average price of $25.10 per share, with a total value of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average price of $25.50 per share, for a total transaction of $25,500.00.

Enovis Price Performance

Shares of NYSE ENOV traded down $0.00 during mid-day trading on Friday, reaching $23.39. The company’s stock had a trading volume of 101,593 shares, compared to its average volume of 1,122,098. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69. The stock has a fifty day moving average of $23.87 and a two-hundred day moving average of $27.88. The firm has a market capitalization of $1.34 billion, a PE ratio of -1.13 and a beta of 1.46.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter last year, the company earned $0.98 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Evercore restated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Needham & Company LLC boosted their target price on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Canaccord Genuity Group dropped their price target on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, UBS Group restated a “buy” rating and set a $50.00 price target on shares of Enovis in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.43.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Arax Advisory Partners purchased a new stake in shares of Enovis during the 4th quarter valued at about $29,000. Farther Finance Advisors LLC increased its stake in Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC purchased a new stake in Enovis during the second quarter valued at approximately $46,000. Finally, SJS Investment Consulting Inc. lifted its stake in shares of Enovis by 30,340.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.